Enrolled
El texto subrayado se agregaría a la ley vigente. El texto tachado se eliminaría.
| H.R. No. 1495 |
| R E S O L U T I O N | |
| BE IT RESOLVED by the House of Representatives of the State of | |
| Texas, 89th Legislature, Regular Session, 2025, That House Rule 13, | |
| Section 9(a), be suspended in part as provided by House Rule 13, | |
| Section 9(f), to enable the conference committee appointed to | |
| resolve the differences on Senate Bill 2308 (the establishment of a | |
| consortium to conduct United States Food and Drug Administration's | |
| drug development clinical trials with ibogaine to secure the | |
| administration's approval of the medication's use for treatment of | |
| opioid use disorder, co-occurring substance use disorder, and any | |
| other neurological or mental health conditions for which ibogaine | |
| demonstrates efficacy and to the administration of that treatment) | |
| to consider and take action on the following matters: | |
| (1) House Rule 13, Section 9(a)(2), is suspended to permit | |
| the committee to omit text not in disagreement by omitting in | |
| proposed SECTION 1 of the bill added Section 491.001(2), Health and | |
| Safety Code. The omitted text reads: | |
| (2) "Executive commissioner" means the executive | |
| commissioner of the Health and Human Services Commission. | |
| Explanation: The change is necessary to remove a definition | |
| that no longer appears in added Chapter 491, Health and Safety Code. | |
| (2) House Rule 13, Section 9(a)(4), is suspended to permit | |
| the committee to add text on a matter not included in either the | |
| house or senate version of the bill in proposed SECTION 1 of the | |
| bill, by adding Sections 491.001(2), (3), (4), and (6), Health and | |
| Safety Code, to read as follows: | |
| (2) "Comptroller" means the comptroller of public | |
| accounts. | |
| (3) "Drug developer" means a pharmaceutical company, | |
| biotechnology company, or contract development and manufacturing | |
| organization engaged in drug development and manufacturing. | |
| (4) "Hospital" has the meaning assigned by Section | |
| 241.003. | |
| (6) "Institution of higher education" has the meaning | |
| assigned by Section 61.003, Education Code. | |
| Explanation: The change is necessary to define | |
| "comptroller," "drug developer," "hospital," and "institution of | |
| higher education" for purposes of added Chapter 491, Health and | |
| Safety Code. | |
| (3) House Rule 13, Section 9(a)(2), is suspended to permit | |
| the committee to omit text not in disagreement in proposed SECTION 1 | |
| of the bill by omitting added Sections 491.002 and 491.003, Health | |
| and Safety Code. The omitted text reads: | |
| Sec. 491.002. RULES. The executive commissioner shall | |
| adopt rules necessary to administer this chapter. | |
| Sec. 491.003. ESTABLISHMENT OF GRANT PROGRAM. The | |
| commission shall establish and administer a grant program to fund a | |
| public-private partnership program that will pay for the costs of | |
| the United States Food and Drug Administration's drug development | |
| trials with ibogaine to secure the administration's approval as a | |
| medication for treatment of opioid use disorder, co-occurring | |
| substance use disorder, and any other neurological or mental health | |
| conditions for which ibogaine demonstrates efficacy. | |
| Explanation: The change is necessary to eliminate rulemaking | |
| authority and remove a grant program. | |
| (4) House Rule 13, Section 9(a)(4), is suspended to permit | |
| the committee to add text on a matter not included in either the | |
| house or senate version of the bill in proposed SECTION 1 of the | |
| bill, by adding a heading for added Subchapter B, Chapter 491, | |
| Health and Safety Code, to read as follows: | |
| SUBCHAPTER B. DRUG DEVELOPMENT OF IBOGAINE TREATMENT | |
| Explanation: The change is necessary for better organization | |
| of added Chapter 491, Health and Safety Code. | |
| (5) House Rule 13, Section 9(a)(4), is suspended to permit | |
| the committee to add text on a matter not included in either the | |
| house or senate version of the bill in proposed SECTION 1 of the | |
| bill, by adding Sections 491.051 and 491.052, Health and Safety | |
| Code, to read as follows: | |
| Sec. 491.051. ESTABLISHMENT OF CONSORTIUM. (a) A | |
| consortium may be established under this section and apply for | |
| commission selection under this subchapter to conduct drug | |
| development clinical trials with ibogaine and secure the United | |
| States Food and Drug Administration's approval of ibogaine as a | |
| medication for the treatment of: | |
| (1) opioid use disorder; | |
| (2) co-occurring substance use disorder; and | |
| (3) any other neurological or mental health condition | |
| for which ibogaine demonstrates efficacy. | |
| (b) A consortium established under this section must | |
| include one or more of each of the following entities: | |
| (1) a drug developer; | |
| (2) an institution of higher education; and | |
| (3) a hospital. | |
| Sec. 491.052. LEAD INSTITUTION; ADMINISTRATION; PERSONNEL. | |
| (a) A consortium established under this subchapter shall select a | |
| lead institution of higher education from among the consortium's | |
| members to represent the consortium and perform administrative | |
| functions under this subchapter, including contracting with and | |
| reporting to the commission as required by this subchapter. | |
| (b) A consortium selected by the commission under this | |
| subchapter may employ personnel, including clinical, | |
| administrative, and data management personnel, necessary to | |
| support any consortium member's activities related to drug | |
| development clinical trials conducted under this subchapter. | |
| Explanation: The change is necessary to allow formation of a | |
| consortium for the conduct of certain drug development clinical | |
| trials, to secure United States Food and Drug Administration's | |
| approval for certain medical treatments, and to allow the | |
| consortium to select a lead institution and employ necessary | |
| personnel. | |
| (6) House Rule 13, Section 9(a)(2), is suspended to permit | |
| the committee to omit text not in disagreement in proposed SECTION 1 | |
| of the bill by omitting the heading and Subsections (a) and (c) of | |
| added Section 491.004, Health and Safety Code. The omitted text | |
| reads: | |
| Sec. 491.004. APPLICATION. (a) The commission shall | |
| prepare and issue a notice of funding opportunity to solicit | |
| applications for the grant program established under this | |
| subchapter. | |
| (c) The commission shall: | |
| (1) make available the application required under this | |
| section; and | |
| (2) announce a period of not less than 90 days during | |
| which applicants may submit an application under this subchapter. | |
| Explanation: The change is necessary to remove an application | |
| process for a removed grant program. | |
| (7) House Rule 13, Section 9(a)(4), is suspended to permit | |
| the committee to add text on a matter not included in either the | |
| house or senate version of the bill in proposed SECTION 1 of the | |
| bill, by adding a heading and Subsection (a) for Section 491.053, | |
| Health and Safety Code, to read as follows: | |
| Sec. 491.053. CONSORTIUM PROPOSAL. (a) The lead | |
| institution of higher education of a consortium shall submit to the | |
| commission a proposal and request for funding on behalf of the | |
| consortium for purposes of conducting ibogaine drug development | |
| clinical trials in accordance with this subchapter. | |
| Explanation: The change is necessary to require a consortium | |
| formed under added Chapter 491, Health and Safety Code, to submit to | |
| the Health and Human Services Commission a proposal for selection | |
| to conduct a drug development clinical trial under that chapter. | |
| (8) House Rule 13, Sections 9(a)(1), (2), and (3), are | |
| suspended to permit the committee to change, alter, or amend text | |
| not in disagreement, omit text not in disagreement, and add text on | |
| a matter not in disagreement in proposed SECTION 1 of the bill, by | |
| adding Section 491.053(b), Health and Safety Code, to read as | |
| follows: | |
| (b) A proposal submitted under Subsection (a) must provide: | |
| (1) the identity of all consortium members; | |
| (2) a detailed description of the planned strategy for | |
| obtaining approval for the drug development clinical trials from | |
| the United States Food and Drug Administration; | |
| (3) a detailed drug development clinical trial design | |
| that includes: | |
| (A) a description of the composition of the | |
| consortium's drug development clinical trial team and the expertise | |
| of the team members; | |
| (B) a drug development clinical trial | |
| participant recruitment plan; | |
| (C) patient screening criteria and cardiac | |
| safety protocols; | |
| (D) administration protocols; | |
| (E) an aftercare and post-acute treatment | |
| support plan; and | |
| (F) a data integrity plan; | |
| (4) a detailed plan to seek a breakthrough therapy | |
| designation for ibogaine from the United States Food and Drug | |
| Administration under 21 U.S.C. Section 356; | |
| (5) a proposal to recognize this state's commercial | |
| interest in all intellectual property that may be generated over | |
| the course of the drug development clinical trials, including: | |
| (A) the treatment that is the subject of the | |
| trials; | |
| (B) administration protocols; | |
| (C) treatment models or techniques; and | |
| (D) technology used in the trials; | |
| (6) a plan to establish a corporate presence in this | |
| state and to promote and maintain ibogaine-related biomedical | |
| research, development, treatment, manufacturing, and distribution | |
| in this state; | |
| (7) a plan to secure third-party payor approval for | |
| ibogaine treatment following approval by the United States Food and | |
| Drug Administration through: | |
| (A) private insurers; | |
| (B) Medicare; | |
| (C) Medicaid; and | |
| (D) the TRICARE program of the United States | |
| Department of Defense; | |
| (8) a plan to ensure ibogaine treatment access to | |
| uninsured individuals following approval by the United States Food | |
| and Drug Administration; | |
| (9) a plan to train and credential medical providers | |
| to administer ibogaine treatment according to developed clinical | |
| standards; and | |
| (10) financial disclosures that verify the | |
| consortium's capacity to fully match state funding with funds | |
| received from non-state sources. | |
| Explanation: The change is necessary to specify the | |
| information required for submission of a proposal under Section | |
| 491.053, Health and Safety Code, and selection to perform drug | |
| development clinical trials under added Chapter 491, Health and | |
| Safety Code. | |
| (9) House Rule 13, Section 9(a)(2), is suspended to permit | |
| the committee to omit text not in disagreement in proposed SECTION 1 | |
| of the bill by omitting added Section 491.005, Health and Safety | |
| Code. The omitted text reads: | |
| Sec. 491.005. SELECTION COMMITTEE. (a) The commission | |
| shall create a selection committee and select the number of | |
| members. The committee must be composed of: | |
| (1) subject matter experts; | |
| (2) philanthropic partners; and | |
| (3) legislative designees. | |
| (b) The selection committee shall review applications, | |
| communicate supplemental inquiries to applicants, and recommend to | |
| the commission the best applicants to conduct the drug development | |
| trials. | |
| (c) The commission shall consider the recommendations of | |
| the selection committee in selecting the applicant to conduct the | |
| ibogaine drug development trial. | |
| Explanation: The change is necessary to remove the selection | |
| committee. | |
| (10) House Rule 13, Section 9(a)(4), is suspended to permit | |
| the committee to add text on a matter not included in either the | |
| house or senate version of the bill in proposed SECTION 1 of the | |
| bill, by adding Sections 491.054 and 491.055, Health and Safety | |
| Code, to read as follows: | |
| Sec. 491.054. COMMISSION SELECTION. The commission, in the | |
| commission's sole discretion, shall select a consortium | |
| established in accordance with Section 491.051 for the purpose of | |
| conducting ibogaine drug development clinical trials under this | |
| subchapter. | |
| Sec. 491.055. CONTRACT WITH LEAD INSTITUTION. (a) As soon | |
| as practicable after selecting a consortium to conduct ibogaine | |
| drug development clinical trials under Section 491.054, the | |
| commission shall enter into an interagency contract, as provided by | |
| Chapter 771, Government Code, with the lead institution of higher | |
| education of the selected consortium to provide funding to | |
| implement the consortium's proposed ibogaine drug development | |
| clinical trials. | |
| (b) The interagency contract described by Subsection (a) | |
| must specify: | |
| (1) the goals and objectives of the proposed ibogaine | |
| drug development clinical trials; | |
| (2) the proposed budget; | |
| (3) the timeline for completing the proposed | |
| objectives; | |
| (4) the for-profit, nonprofit, or public benefit | |
| corporate entities collaborating with the consortium in the drug | |
| development clinical trials under this subchapter; | |
| (5) the percentage of the revenue arising from the | |
| drug development clinical trials to be paid to the state; and | |
| (6) any other information required by the commission. | |
| (c) As soon as practicable after entering into an | |
| interagency contract under Subsection (a), the commission shall | |
| report the existence of the contract to the legislature. | |
| (d) The commission may not disburse funds to or for a | |
| selected consortium under the interagency contract described by | |
| Subsection (a) until the consortium receives and the commission | |
| verifies the receipt of matching funds from sources other than the | |
| state. | |
| Explanation: The change is necessary to allow the Health and | |
| Human Services Commission to select a consortium established under | |
| added Chapter 491, Health and Safety Code, for the purpose of | |
| conducting drug development clinical trials under that chapter, to | |
| require the commission to enter into an interagency contract with | |
| the consortium for the conduct of those trials, and to regulate the | |
| contract provisions and the disbursement of funds to the selected | |
| consortium. | |
| (11) House Rule 13, Sections 9(a)(1) and (3), are suspended | |
| to permit the committee to change, alter, or amend text not in | |
| disagreement and add text on a matter not in disagreement in | |
| proposed SECTION 1 of the bill, by adding Section 491.056, Health | |
| and Safety Code, to read as follows: | |
| Sec. 491.056. INVESTIGATIONAL NEW DRUG APPLICATION. On the | |
| commission's notification that a consortium is selected to conduct | |
| the drug development clinical trials under this subchapter, a drug | |
| developer or hospital member of the selected consortium or the lead | |
| institution of higher education of the consortium, as specified by | |
| written agreement of the consortium members, shall, as soon as | |
| practicable: | |
| (1) submit an investigational new drug (IND) | |
| application to the United States Food and Drug Administration in | |
| accordance with 21 C.F.R. Part 312; and | |
| (2) seek a breakthrough therapy designation for | |
| ibogaine from the United States Food and Drug Administration under | |
| 21 U.S.C. Section 356. | |
| Explanation: The change is necessary to allow certain members | |
| of a consortium established under added Chapter 491, Health and | |
| Safety Code, to apply for an investigational new drug application | |
| with the United States Food and Drug Administration and to seek from | |
| the administration a breakthrough therapy designation for certain | |
| treatments. | |
| (12) House Rule 13, Section 9(a)(4), is suspended to permit | |
| the committee to add text on a matter not included in either the | |
| house or senate version of the bill in proposed SECTION 1 of the | |
| bill, by adding Section 491.057, Health and Safety Code, to read as | |
| follows: | |
| Sec. 491.057. DRUG DEVELOPMENT CLINICAL TRIAL SITES. For | |
| purposes of conducting a drug development clinical trial under this | |
| subchapter, only an institution of higher education or a hospital | |
| may serve as a trial site. | |
| Explanation: The change is necessary to specify which members | |
| of a consortium established under added Chapter 491, Health and | |
| Safety Code, may serve as a drug development clinical trial site | |
| under that chapter. | |
| (13) House Rule 13, Section 9(a)(2), is suspended to permit | |
| the committee to omit text not in disagreement in proposed SECTION 1 | |
| of the bill by omitting added Sections 491.007 and 491.008, Health | |
| and Safety Code. The omitted text reads: | |
| Sec. 491.007. ESTABLISHMENT OF DRUG DEVELOPMENT TRIAL | |
| SITES. On approval of the applicant's investigational new drug | |
| application by the United States Food and Drug Administration, the | |
| commission shall, in consultation with the applicant, establish | |
| drug development trial sites that must be equipped and staffed to | |
| provide cardiac intensive care services to patients. | |
| Sec. 491.008. CONDUCTING DRUG DEVELOPMENT TRIAL. (a) As | |
| soon as practicable after drug development trial sites are | |
| established under Section 491.007, the applicant shall begin a drug | |
| development trial to administer treatment with ibogaine. | |
| (b) The commission, in consultation with the selection | |
| committee under Section 491.005, shall select an institutional | |
| review board with a presence in this state to oversee and verify the | |
| drug development trial research activity for scientific validation | |
| and authentication under the requirements of the United States Food | |
| and Drug Administration. | |
| (c) The applicant shall request the designation under 21 | |
| U.S.C. Section 356 during the drug development trial if the | |
| ibogaine treatment is demonstrating efficacy. | |
| Explanation: The change is necessary to remove requirements | |
| relating to drug development trial sites and the conduct of a drug | |
| development trial. | |
| (14) House Rule 13, Sections 9(a)(1), (2), and (4), are | |
| suspended to permit the committee to change, alter, or amend text | |
| not in disagreement, omit text on a matter not in disagreement, and | |
| add text on a matter not included in either the house or senate | |
| version of the bill in proposed SECTION 1 of the bill, by adding | |
| Section 491.058, Health and Safety Code, to read as follows: | |
| Sec. 491.058. FUNDING; DISBURSEMENT BY COMMISSION. (a) | |
| The commission and consortium members may solicit and accept gifts, | |
| grants, and donations of any kind received from sources other than | |
| the state for purposes of funding drug development clinical trials | |
| under this subchapter. | |
| (b) Disbursements of funds by the commission may be made | |
| incrementally based on the completion of clearly defined objectives | |
| as negotiated in the contract described by Section 491.055, | |
| including verifiable documentation demonstrating the efficient | |
| expenditure of both state and matching funds. | |
| Explanation: The change is necessary to clarify that matching | |
| funds provided by a consortium established under added Chapter 491, | |
| Health and Safety Code, must come from sources other than the state, | |
| and to add accountability requirements. | |
| (15) House Rule 13, Section 9(a)(2), is suspended to permit | |
| the committee to omit text not in disagreement in proposed SECTION 1 | |
| of the bill by omitting added Section 491.009(b), Health and Safety | |
| Code. The omitted text reads: | |
| (b) An applicant selected to perform a drug development | |
| trial under this subchapter shall contribute toward the cost of | |
| developing the ibogaine treatment an amount of money that is at | |
| least equal to the amount of money that the applicant received in | |
| the form of a grant from the commission. | |
| Explanation: The change is necessary to eliminate | |
| duplicative and conflicting provisions relating to matching funds. | |
| (16) House Rule 13, Section 9(a)(4), is suspended to permit | |
| the committee to add text on a matter not included in either the | |
| house or senate version of the bill in proposed SECTION 1 of the | |
| bill, by adding Sections 491.059, 491.060, and 491.061, Health and | |
| Safety Code, to read as follows: | |
| Sec. 491.059. REPORTING REQUIREMENTS. (a) A consortium | |
| selected to conduct ibogaine drug development clinical trials shall | |
| quarterly prepare and submit to the commission: | |
| (1) a report on the progress of the drug development | |
| clinical trials conducted under this subchapter; and | |
| (2) a financial status report, including information | |
| to verify expenditures of state funds and required matching funds. | |
| (b) The commission shall submit a report to the legislature | |
| on the progress of the drug development clinical trials conducted | |
| under this subchapter not later than December 1 of each year. | |
| Sec. 491.060. ALLOCATION OF REVENUE ATTRIBUTABLE TO | |
| INTELLECTUAL PROPERTY AND OTHER RIGHTS. (a) The revenue | |
| attributable to all intellectual property rights and other | |
| commercial rights arising from drug development clinical trials | |
| conducted by a consortium under this subchapter during the period | |
| for which the trials are funded and any following period of | |
| commercialization shall be allocated as follows: | |
| (1) not less than 20 percent to the state as specified | |
| in the contract under Section 491.055; and | |
| (2) the remainder to the members of the consortium in | |
| the amounts specified by written agreement of the members. | |
| (b) For purposes of this section, intellectual property | |
| rights and other commercial rights arising from the drug | |
| development clinical trials conducted under this subchapter | |
| include any of the following as related to the trials: | |
| (1) intellectual property, technology, and | |
| inventions; | |
| (2) patents, trademarks, and licenses; | |
| (3) proprietary and confidential information; | |
| (4) trade secrets, data, and databases; | |
| (5) tools, methods, and processes; | |
| (6) treatment models or techniques; | |
| (7) administration protocols; and | |
| (8) works of authorship. | |
| Sec. 491.061. USE OF STATE REVENUE. (a) The comptroller | |
| shall deposit the revenue received under Section 491.060 to the | |
| credit of the general revenue fund. | |
| (b) Of the amount deposited under Subsection (a), 25 percent | |
| may be appropriated only to programs that assist veterans in this | |
| state. | |
| (c) The comptroller shall develop accounting procedures for | |
| the purpose of implementing this section. | |
| Explanation: The change is necessary to establish reporting | |
| requirements for a consortium established under added Chapter 491, | |
| Health and Safety Code, and to clarify the allocation of revenues | |
| attributable to certain property rights under that chapter. | |
| (17) House Rule 13, Section 9(a)(4), is suspended to permit | |
| the committee to add text on a matter not included in either the | |
| house or senate version of the bill in proposed SECTION 2 of the | |
| bill, by adding Subsection (b) to read as follows: | |
| (b) The Health and Human Services Commission shall begin | |
| accepting proposals from consortiums under Chapter 491, Health and | |
| Safety Code, as added by this Act, not later than the 60th day after | |
| the effective date of this Act. | |
| Explanation: The change is necessary to require the Health | |
| and Human Services Commission to begin accepting proposals from | |
| consortiums under added Chapter 491, Health and Safety Code, by a | |
| certain date. | |
| Harris | |
| ______________________________ | |
| Speaker of the House | |
| I certify that H.R. No. 1495 was adopted by the House on June | |
| 1, 2025, by the following vote: Yeas 121, Nays 15, 1 present, not | |
| voting. | |
| ______________________________ | |
| Chief Clerk of the House | |
Texto oficial de la Legislatura de Texas. El formato se adaptó para leerlo en Ratifi.